Online citations, reference lists, and bibliographies.
← Back to Search

Smooth Blood Pressure Control Obtained With Extended-Release Felodipine In Elderly Patients With Hypertension

R. Antonicelli, S. Omboni, C. Giovanni, R. Ansuini, Alfredo Mori, R. Gesuita, G. Parati, E. Paciaroni
Published 2002 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
ObjectiveTo assess, by smoothness index (SI), distribution of the antihypertensive effect of extended-release (ER) felodipine over 24 hours in elderly patients with hypertension.MethodsAfter a 4-week washout phase, 35 elderly patients (mean age 69 ± 4 years) with mild-to-moderate hypertension received 2 weeks’ treatment with ER felodipine 5mg once daily. The dosage of ER felodipine was doubled to 10 mg/day and given for a further 2 weeks in non-responders (sitting clinic blood pressure > 140/90mm Hg). The study had an open-label design with no placebo control. After each period, clinic and ambulatory blood pressures were measured. Trough-to-peak (T/P) ratio was computed by dividing the blood pressure (BP) change at trough (22 to 24 hours after drug intake) by the change at peak (2 adjacent hours with a maximal BP reduction between the second and eighth hour after drug intake). SI was calculated as the ratio between the average of the 24, hourly, treatment-induced BP changes and its standard deviation.ResultsAfter the initial 2-week treatment period, clinic and 24-hour ambulatory BP values were higher in non-responders (145 ± 11/87 ± 8 and 135 ± 17/80 ± 6mm Hg, respectively) than in responders (133 ± 6/81 ± 3 and 130 ± 9/77 ± 7mm Hg). In non-responders, clinic and 24-hour BP values were lowered after a further 2 weeks of treatment with ER felodipine 10 mg/day (128 ± 11/78 ± 6 and 128 ± 12/75 ± 5mm Hg). SI was high in responders (0.8 ± 0.8/0.7 ± 0.7 for systolic/diastolic BP) and low in non-responders (0.5 ± 0.6/0.3 ± 0.6) during the first 2-week treatment period. It increased in non-responders after an additional 2 weeks of treatment with ER felodipine 10 mg/day (1.0 ± 0.8/0.7 ± 0.6). Median T/P ratios were 0.73 and 0.61 (systolic BP and diastolic BP) in responders and 0.41 and 0.61 in non-responders after 2 weeks of treatment. At variance with SI, T/P ratios did not increase in non-responders after doubling the dosage of ER felodipine (0.34 and 0.18). ER felodipine did not increase 24-hour heart rate. A total of nine adverse events were recorded in six patients (17%), but no patients withdrew from the study.ConclusionER felodipine 5 to 10 mg/day smoothly and safely reduces 24-hour ambulatory BP in elderly patients with hypertension.
This paper references
Evaluation of cardiovascular risk in the elderly: the Framingham study.
W. Kannel (1978)
10.1097/00004872-198702000-00013
Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension.
G. Parati (1987)
10.1016/0002-8703(87)90666-1
Heart rate and cardiovascular mortality: the Framingham Study.
W. Kannel (1987)
Epidemiology and risk of hypertension in the elderly: the Framingham Study.
P. Vokonas (1988)
Ambulatory blood pressure monitoring in the design of antihypertensive drug trials.
J. Conway (1991)
Felodipine once daily in elderly hypertensives. Binational MC Study Group (United Kingdom and Netherlands).
J. Hosie (1991)
10.2165/00002512-199202050-00002
Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in older patients.
D. Faulds (1992)
10.1001/ARCHINTE.1992.00400210081013
Clinical relevance of nighttime blood pressure and of daytime blood pressure variability.
P. Palatini (1992)
10.1161/01.HYP.21.4.510
Ambulatory blood pressure monitoring use in hypertension research and clinical practice.
G. Mancia (1993)
10.1056/NEJM199304013281303
Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
B. J. Materson (1993)
10.1161/01.HYP.22.3.392
1993 guidelines for the management of mild hypertension. Memorandum from a World Health Organization/International Society of Hypertension meeting. Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee.
Lippincott Williams Wilkins (1993)
10.1097/00004872-199310000-00019
Prognostic value of 24-hour blood pressure variability
A. Frattola (1993)
10.1161/01.HYP.23.3.395
Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction.
S. Madhavan (1994)
Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension.
T. Fagan (1994)
The physiologic relevance of smooth twenty-four-hour blood pressure control.
A. Zanchetti (1994)
10.1097/00004872-199510000-00005
Calculation of trough: peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects
S. Omboni (1995)
10.3109/08037059509077587
Ambulatory blood pressure monitoring in the evaluation of antihypertensive treatment: additional information from a large data base.
G. Mancia (1995)
10.1007/BF03324282
Blood pressure variability and reflex control in the elderly
G. Mancia (1995)
10.1016/0895-7061(94)00250-F
Lack of placebo effect on ambulatory blood pressure.
G. Mancia (1995)
10.1097/00004872-199610003-00003
Current position of calcium antagonists in hypertension
A. Zanchetti (1996)
Low dosages of felodipine ER once daily as monotherapy in elderly hypertensive patients : effect on ambulatory blood pressure and quality of life
J. W. Ree (1996)
10.1161/01.CIR.95.6.1464
Ambulatory Blood Pressure Is Superior to Clinic Blood Pressure in Predicting Treatment-Induced Regression of Left Ventricular Hypertrophy
G. Mancia (1997)
10.1097/00004872-199715010-00001
Heart rate and the cardiovascular risk
P. Palatini (1997)
10.1016/S0140-6736(97)05381-6
Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
J. Staessen (1997)
10.1001/archinte.157.21.2413
The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI)
Detection (1997)
10.1111/j.1532-5415.1997.tb01475.x
Blood Pressure Reduction and Tolerability of Felodipine ER in Older and Younger Hypertensive Patients
T. Fagan (1997)
10.1016/S0002-9149(97)00722-4
Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure.
E. Grossman (1997)
10.1097/00004872-199715070-00005
Longitudinal association of ambulatory pulse pressure with left ventricular mass and vascular hypertrophy in essential hypertension
R. Khattar (1997)
10.1016/S0140-6736(98)04311-6
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
L. Hansson (1998)
10.1161/01.HYP.32.6.983
Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension.
P. Verdecchia (1998)
The trough:peak ratio and the smoothness index in the evaluation of control of 24 h blood pressure by treatment in hypertension.
Omboni (1998)
10.1097/00004872-199816070-00008
Risk factors associated with alterations in carotid intima—media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis
A. Zanchetti (1998)
10.1038/sj.jhh.1000668
Cardiovascular risk factors in the elderly
E. Casiglia (1998)
10.1097/00004872-199816110-00016
The smoothness index: A new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension
G. Parati (1998)
10.1161/01.HYP.32.3.560
Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects.
A. Benetos (1998)
A comparison of nisoldipine coat-core and felodipine in the treatment of mild-to-moderate hypertension.
C. Hoglund (1998)
10.1097/00004872-199816120-00017
Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements
S. Omboni (1998)
10.1161/01.CIR.100.4.354
Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study.
S. Franklin (1999)
10.1097/00004872-199917010-00020
Double-blind, randomized, multicentre comparison of the effects of amlodipine and perindopril on 24 h therapeutic coverage and beyond in patients with mild to moderate hypertension
F. Zannad (1999)
10.1097/00004872-199917020-00001
[The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, and 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension].
M. Ishii (2000)
10.1016/S0140-6736(00)02527-7
Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
M. Brown (2000)
10.1007/BF00877817
Hypertension in the elderly: Age- and disease-related complications and therapeutic implications
E. Lakatta (2004)



This paper is referenced by
10.1097/HJH.0000000000002236
The smoothness index: an 'all purposes' approach to the assessment of the homogeneity of 24-h blood pressure control?
D. Rizzoni (2019)
Method Development, Validation and Stability Studies of Felodipine by RP-HPLC and Molecular Interaction Studies of Felodipine and Voltage Gated L-type Calcium Channel
Aravind Setti (2014)
10.1038/hr.2013.145
Blood pressure variability over 24 h: prognostic implications and treatment perspectives. An assessment using the smoothness index with telmisartan–amlodipine monotherapy and combination
G. Parati (2014)
10.1136/heartjnl-2013-304238
Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4121 patients with focus on trial design: the CONVERGE report
J. Howard (2013)
10.4236/PP.2010.12007
Rational Drug Delineation: A Global Sensitivity Approach Based on Therapeutic Tolerability to Deviations in Execution
Denis Goue Gohore (2010)
10.1007/978-1-60327-362-6_22
Drug–Nutrient Interactions in the Elderly
B. Kinosian (2009)
10.2146/ajhp060663
Role of ambulatory blood pressure monitoring in the management of hypertension.
Kathleen Chavanu (2008)
10.1007/978-1-59259-978-3_13
Ambulatory Blood Pressure in Older Patients
L. Prisant (2007)
10.1080/08037050600996628
Clinical utility and applicability of smoothness index, normalized smoothness index and individualized RDH index during treatment of essential hypertension
A. Stenehjem (2006)
10.1142/S0192415X05002977
Anti-hypertensive effect of chunghyul-dan (qingxue-dan) on stroke patients with essential hypertension.
S. P. Yun (2005)
éñÖçäÄ êÄÇçéåÖêçéëíà ÄçíàÉàèÖêíÖçáàÇçéÉé ùîîÖäíÄ ÑÇìï ãÖäÄêëíÇÖççõï îéêå çàîÖÑàèàçÄ ë èéåéôúû ëìíéóçéÉé åéçàíéêàêéÇÄçàü ÄêíÖêàÄãúçéÉé ÑÄÇãÖçàü
V. Gorbunov (2005)
Semantic Scholar Logo Some data provided by SemanticScholar